Professional
Added to YB: 2025-02-21
Pitch date: 2025-01-28
INDV [bullish]
Indivior PLC
+189.58%
current return
Author Info
No bio for this author
Company Info
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
Market Cap
GBP 1.2B
Pitch Price
GBP 12.28
Price Target
N/A
Dividend
N/A
EV/EBITDA
3.72
P/E
-25.44
EV/Sales
1.01
Sector
Pharmaceuticals
Category
turnaround
Summers Value Fund Portfolio Holding: Indivior PLC
INDV: Opioid addiction drug Sublocade sales forecast cut due to Brixadi competition. sNDA filed for improved dosing, approval expected Feb. Long-acting agents underpenetrated (5-6% of prescriptions). Position at $7.74/share, 10x expected EPS. Potential for market expansion & share recovery.
Read full article (1 min)